July 1st 2012
Over the next few years over 25 current blockbuster drugs such as Lipitor, Plavix and Advair will lose major product patent protection. No doubt the branded industry will defend these products and the generics sector will seek approvals for generic alternatives.
Knowledge of a product’s patent status and data exclusivity is critical:
Accessing and assessing European patent and IP data is complex, which is why MPA’s European Patent Status Review is essential. Produced by leading and experienced European pharmaceutical business intelligence specialists MPA Business Services, and available via Espicom, this constantly updated database will rapidly provide reliable access to the key patent information you need.
For over 1,500 molecules marketed in 27 markets this service provides data including:
MPA’s European Drug Patent Status Review is an interactive web-based subscription service. Highly cost-effective pricing means the service can be taken on a country-by-country or European-wide basis.
In addition, varying levels of MPA’s market-leading consultancy services are included in all of its subscription packages.
To arrange a demonstration or find out more about price and distribution, please click on the link to contact firstname.lastname@example.org